Dr John Melki – CEO and Director – Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.
Copyright 2023 – Finance News Network
27 May 2021 - QEM Limited (ASX:QEM) Managing Director Gavin Loyden discusses the invention and advantages of vanadium redox flow batteries with Professor Maria Skyllas-Kazacos of the University of New South Wales.
29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
24 Nov 2020 - Imdex (ASX:IMD) Limited CEO Paul House discusses the company's financial update, outlook and strategy, and provides an introduction to its technology, which improves the productivity of drill rigs, data collection and analysis.
25 May 2021 - Skyfii Limited (ASX:SKF) CEO & Managing Director Wayne Arthur talks about the company's SaaS cloud-based solution that helps venues visualise, measure, predict and influence customer behaviour, creating better experiences for their visitors and customers.
30 May 2022 - Fred Pye, CEO and Chairman of digital asset manager 3iQ, discusses the future of cryptocurrencies and the launch of two crypto ETFs in Australia based on Ethereum and Bitcoin.
31 Mar 2021 - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) CEO and Managing Director James Graham talks about progress with the company's lead anti-infective candidate Recce 327, its expanding portfolio of synthetic anti-infectives targeting viral pathogens and a broad range of bacteria, clinical trial results and priorities for 2021.
06 Sep 2022 - Kinetiko Energy Limited (ASX:KKO) CEO Nick de Blocq discusses the South African energy market and the role of gas in the clean energy transition.
22 Sep 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses Evergrande, the Chinese economy, implications for the Australian equity market and monetary policy.
29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.